Long term Buy Call For Cipla

Long term Buy Call For CiplaTechnical analyst Sanjeev Bhasin has maintained 'hold' rating on Bharti Airtel stock with a target of Rs 350.

According to analyst, the said target can be attained within a period of six months.

The stock of the company, on May 04, closed at Rs 309.35 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 380.80 and a low of Rs 289.75 on BSE.

Current EPS & P/E ratio stood at 11.63 and 26.29 respectively.

As per reports, a conference of the company's Board of Directors will take place on May 05, 2011, to consider unaudited financial outcomes for the three month period ended March 31, 2011.      Cipla Ltd is a well-known Indian drug company, famous outside its home country for fabricating low-priced anti-AIDS drugs for HIV-positive sufferers in nations.

Set up by Khwaja Abdul Hamied in the year 1935, the company manufactures drugs to treat heart problems, arthritis, diabetes, obesity, depressive disorder and many other health linked problems, and its products are distributed in over 180 nations all over the world.

Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate